Over the past three decades, prevention and treatment of ASCVD were mainly concentrated on regimens regulating LDL-cholesterol via statins and PCSK9 (proprotein convertase subtilisin/kexin type 9)-blocking antibodies, and therapies targeting other traditional risk factors (Bergheanu et al. 2017; Li et al. 2022a, b). This evidence concerns the gene PCSK9 and atherosclerosis.